Case Report: Immune checkpoint inhibitor-induced gastrointestinal toxicity: the diagnostic challenge of sequential ileus and colitis. (PubMed, Front Med (Lausanne)) - Oct 10, 2026 - "We describe the clinical course, investigation, and management of a patient with metastatic esophageal mucosal melanoma who developed sequential gastrointestinal toxicities following combination ipilimumab and nivolumab therapy, focusing on early recognition and the diagnostic challenges associated with recognizing immune-mediated intestinal dysmotility...Following an initial response to prolonged corticosteroid treatment, diarrhea recurred and ultimately improved after infliximab therapy...Recognition of the contrasting clinical phenotypes, particularly otherwise unexplained nausea, vomiting, constipation, and bowel dilatation without mechanical obstruction, is essential because the underlying mechanisms and therapeutic responses may differ. Greater awareness of these early warning features, coupled with prompt investigation and multidisciplinary assessment, may reduce diagnostic delays and enable earlier treatment of this potentially life-threatening toxicity."
Checkpoint inhibition • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor
|
|
Brent O'Carrigan; Mouhamad Ismail; Nicola Thompson; Philippa Corrie
|